Holen Sie sich die Stockscreener-App
54.65
0.18%
0.10
Schlusskurs vom Vortag:
$54.55
Offen:
$54.52
24-Stunden-Volumen:
15.40M
Relative Volume:
6.10
Marktkapitalisierung:
$4.50B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-269.44M
KGV:
-14.57
EPS:
-3.75
Netto-Cashflow:
$-262.63M
1W Leistung:
+0.29%
1M Leistung:
+1.13%
6M Leistung:
-0.11%
1J Leistung:
+75.61%
1-Tages-Spanne:
$54.37
$54.83
1-Wochen-Bereich:
$54.30
$54.83
52-Wochen-Spanne:
$21.34
$58.40
Akero Therapeutics Inc Stock (AKRO) Company Profile
Firmenname
Akero Therapeutics Inc
Sektor
Branche
Telefon
650-487-6488
Adresse
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Vergleichen Sie AKRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
54.65 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
437.92 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.15 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.13 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
893.47 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.88 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-04 | Eingeleitet | TD Cowen | Buy |
| 2025-01-30 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-01-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-11-18 | Eingeleitet | Citigroup | Buy |
| 2024-04-22 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-19 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-08-28 | Eingeleitet | UBS | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | Eingeleitet | BofA Securities | Buy |
| 2021-02-26 | Eingeleitet | Guggenheim | Buy |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-07-01 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Evercore ISI | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-15 | Eingeleitet | Jefferies | Buy |
| 2019-07-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten
Novo Nordisk A/S (CPSE: NOVO B) completed the acquisition of Akero Therapeutics, Inc.. - marketscreener.com
Novo Nordisk Concludes Up to $5.2 Billion Takeover of Akero Therapeutics - marketscreener.com
Akero Therapeutics completes merger with Novo Nordisk, delists from Nasdaq By Investing.com - Investing.com Canada
Akero Therapeutics completes merger with Novo Nordisk, delists from Nasdaq - Investing.com
Novo Nordisk buys Akero Therapeutics in $5.2B deal - breakingthenews.net
Novo Nordisk completes $4.7 billion acquisition of Akero Therapeutics - Investing.com
Vivo Capital LLC Buys 233,521 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics Announces Board and Executive Changes Following Merger - TradingView
Novo Nordisk completes acquisition of Akero Therapeutics - marketscreener.com
Novo Nordisk has completed its acquisition of Akero Therapeutics - GlobeNewswire
(AKRO) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Aug Mood: Why Akero Therapeutics Inc stock could benefit from AI revolution2025 Market WrapUp & Technical Pattern Based Buy Signals - BỘ NỘI VỤ
Akero Therapeutics, Inc. $AKRO Stock Holdings Lessened by Marshall Wace LLP - MarketBeat
JPMorgan Chase & Co. Sells 18,890 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Akero Therapeutics, Inc. $AKRO Position Boosted by Schroder Investment Management Group - MarketBeat
Akero Therapeutics, Inc. $AKRO Shares Sold by Russell Investments Group Ltd. - MarketBeat
Is Akero Therapeutics Inc. (0K4) stock a contrarian opportunity2025 Market Outlook & Low Risk Profit Maximizing Plans - Newser
Will Akero Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Spike Watch & Low Risk Profit Maximizing Plans - Newser
What dividend safety rating applies to Akero Therapeutics Inc. (0K4) stockWeekly Market Outlook & Weekly Stock Performance Updates - Newser
Can Akero Therapeutics Inc. (0K4) stock deliver strong annual returnsWeekly Stock Analysis & Daily Price Action Insights - Newser
Novo Nordisk wins German approval to buy Akero Therapeutics - MLex
Germany's cartel office says it approved acquisition of Akero Therapeutics by Novo Nordisk - marketscreener.com
Key facts: Novo Nordisk launches Ozempic in India; Dr Reddy's court nod; Akero acquisition approved - TradingView
Novo Nordisk-Akero Therapeutics deal gets green light in US - MLex
Akero Therapeutics shareholders approve acquisition by Novo Nordisk - Investing.com Nigeria
Akero Therapeutics stockholders approve acquisition by Novo Nordisk - marketscreener.com
Akero Therapeutics Shareholders Approve Novo Nordisk Merger - TipRanks
Prudential Financial Inc. Purchases 48,055 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Published on: 2025-12-02 04:35:40 - Newser
How Akero Therapeutics Inc. (0K4) stock moves on employment dataJuly 2025 Gainers & Free Reliable Trade Execution Plans - Newser
Loomis Sayles & Co. L P Acquires 51,850 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
SG Americas Securities LLC Sells 1,150,442 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
F m Investments LLC Has $960,000 Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics - The National Law Review
Is Akero Therapeutics Inc a good long term investmentMoving Average Strategies & Free High Profit Capital Plays - earlytimes.in
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
7,107 Shares in Akero Therapeutics, Inc. $AKRO Bought by DLD Asset Management LP - MarketBeat
Rhenman & Partners Asset Management AB Acquires 105,100 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
5,700 Shares in Akero Therapeutics, Inc. $AKRO Bought by North Star Asset Management Inc. - MarketBeat
Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc.AKRO - Business Wire
(AKRO) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Foresite Capital Management VI LLC Has $13.07 Million Stock Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
Creative Planning Purchases 25,643 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Ensign Peak Advisors Inc Has $10.05 Million Holdings in Akero Therapeutics, Inc. $AKRO - MarketBeat
What drives Akero Therapeutics Inc 0K4 stock priceAnalyst Upgrades & Fast Growing Stocks - earlytimes.in
Akero Therapeutics, Inc. $AKRO Shares Sold by Geode Capital Management LLC - MarketBeat
Intech Investment Management LLC Sells 16,635 Shares of Akero Therapeutics, Inc. $AKRO - MarketBeat
Will Akero Therapeutics Inc. (0K4) stock outperform value peersPortfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Halper Sadeh LLC Encourages SEE, AXTA, SEMR, AKRO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Akero Therapeutics Inc. stock a smart buy before Fed meetingIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is Akero Therapeutics Inc. (0K4) stock a top pick for value investorsPrice Action & Reliable Price Breakout Signals - newser.com
Finanzdaten der Akero Therapeutics Inc-Aktie (AKRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):